Short answer
UTAH MEDICAL PRODUCTS INC (UTMD) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $9M (down 14.3% year over year) with net income of $3M.
Q2 2026 key financials · XBRL
- Revenue
- $9M
- −14.3% YoY · −2.2% QoQ
- Net income
- $3M
- −11.9% YoY · +3.1% QoQ
- Operating margin
- 31.1%
- Gross margin
- 55.8%
- EPS (diluted)
- $0.84
- −10.6% YoY · +2.4% QoQ
Source: XBRL data from the UTAH MEDICAL PRODUCTS INC (UTMD) Q2 2026 10-Q on SEC EDGAR. USD.
UTAH MEDICAL PRODUCTS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- 2Q revenue $8.529M, down 14.3% YoY from $9.953M
- Operating margin 31.1% vs 32.1%; net margin 31.5% vs 30.6%
- Best category: Obstetrics $1.066M, up from $1.025M; worst: Blood Pressure Monitoring $1.264M vs $2.019M
- Cash and investments $87.5M vs $85.8M; dividends $2.0M, buybacks $0.2M, capex $0.3M in 1H
- 2026 revenue guidance: down 10–13%; litigation expense estimate below $1.6M vs $1.355M in 2025
Risk Factors
- No risk-factors section provided in the filing excerpt
- 1,207 open-market shares repurchased during 2Q 2026 at average $64.10 per share
- Share repurchases depend on seller availability and stock price
- Repurchases lack an expiration date or maximum dollar or share limit
- Nasdaq listing preserved through restriction against terminating exchange eligibility
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other UTAH MEDICAL PRODUCTS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.